NEW ARTICLE - Comparison of mAb single-use DSP processes by Sanofi using Ypso-Proxima

EASY: a disruptive mAb purification process to reduce cost of goods

• by Ypso-Facto
• January 08, 2021

This article [1] illustrates how Ypso-Proxima allows a rational comparison between two biopharmaceutical DSP processes.

The innovative EASY mAb purification process developed by Sanofi is matched against the standard proteinA-based DSP counterpart.

Relying on Proxima's process evaluation, the study highlights reduced Cost of Goods (COGs) and process duration with EASY, for a single batch and over a 10-batch campaign.

This demonstrates the power of this new, single-use flow-through approach for the first clinical batches in early-stage GMP production.

Read more here.

[1] T. Prouzeau, et al., “EASY: a Disruptive mAb Purification Process to Reduce Cost of Goods,” BioPharm International 34 (1) 26–30 (2021)

---